Clinical Trials Logo

Alcohol Dependence clinical trials

View clinical trials related to Alcohol Dependence.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06308484 Recruiting - Alcohol Dependence Clinical Trials

Neuromodulation and Mindfulness Patients With AUD

Start date: March 20, 2024
Phase: N/A
Study type: Interventional

Our primary objective is to integrate tVNS and mindfulness meditation within a structured mindfulness-based relapse prevention (MBRP) program for detoxified alcohol-dependent patients (AD). We aim to determine whether neuromodulation can enhance mindfulness-based relapse prevention compared to mindfulness practice alone. In this context, we will investigate potential changes in the interaction of top-down control and cue reactivity, as well as assess the severity of AUD. Measurements of drinking behavior, cravings, and abstinence rates will be conducted up to three months post-treatment. Our second objective is to examine the causal role of frontal midline theta oscillations (FMΘ) in MBRP and cognitive control. To achieve this, we will first establish closed-loop amplitude-modulated transcranial alternating current stimulation (CLAM-tACS) to selectively modulate FMΘ oscillations during MBRP meditation exercises in AUD patients (2).

NCT ID: NCT06262958 Recruiting - Clinical trials for Substance Use Disorders

Recognition and Early Intervention for Alcohol and Substance Abuse in Adolescence in Adolescent

REAL-SMART
Start date: August 7, 2017
Phase: N/A
Study type: Interventional

ASSIST mini-intervention is applied in an electric form in adolescent outpatients to see if it

NCT ID: NCT05963659 Recruiting - Alcohol Dependence Clinical Trials

Nitrate Modulates Cognitive Impairment Via Oral Microbiota.

Start date: September 10, 2023
Phase: N/A
Study type: Interventional

Alcohol use is increasingly prevalent in modern society and is known to cause cognitive impairment and dysregulation of inflammatory responses. In the present study, the investigators want to perform a randomised controlled trials to test whether nitrate could change the oral microbiota and benefit the cognitive impairment in alcohol dependence patients. The investigators survey the oral bacterial communities in saliva samples of 70 alcohol dependent patients following 14 days of dietary inorganic nitrate (nitrate-rich beetroot juice, ~750 mg NO3- /d) and placebo (nitrate-depleted beetroot juice, ~1 mg NO3- /d) supplementation.

NCT ID: NCT05895643 Recruiting - Clinical trials for Alcohol Use Disorder

Does Semaglutide Reduce Alcohol Intake in Patients With Alcohol Use Disorder and Comorbid Obesity?

SEMALCO
Start date: June 13, 2023
Phase: Phase 2
Study type: Interventional

This 26-week long, double-blinded randomized clinical trial aims to investigate the effects of the GLP-1 receptor agonist semaglutide s.c. vs placebo on alcohol consumption in 108 patients diagnosed with alcohol use disorder and comorbid obesity (BMI>30 kg/m2). Patients will be treated for 26 weeks with semaglutide subcutaneously (s.c.) once weekly or placebo. The medication will be provided as a supplement to standardised cognitive behavioural therapy. A subgroup of the patients will have two brain scans (Magnetic Resonance Spectroscopy (MRS) and functional Magnetic Resonance Imaging (fMRI)) conducted in one scan session at week 0 and 26. The primary endpoint is the percentage-point reduction in total number of heavy drinking days, defined as days with an excess intake of 48/60 grams of alcohol per day (women and men, respectively) from baseline to follow-up after 26 weeks of treatment, measured by the timeline followback (TLFB) method.

NCT ID: NCT05854693 Recruiting - Alcohol Dependence Clinical Trials

Trans-cranial Direct Current Stimulation on Alcohol Craving

Start date: April 17, 2023
Phase: N/A
Study type: Interventional

The goal of thisclinical trial is to investigate the efficacy of trans cranial direct current stimulation (tDCS) for alcohol craving in individuals with alcohol dependence. The main question it aims to answer is whether 10 sessions of tDCS can reduce craving for alcohol. Participants will be randomized into active group and sham group. Researchers will compare the severity of craving in these groups.

NCT ID: NCT05738174 Recruiting - Alcohol Dependence Clinical Trials

High-dose Accelerated Theta Burst Stimulation for the Treatment of Alcohol Addiction

TBA
Start date: March 1, 2023
Phase: N/A
Study type: Interventional

This is a two-arm randomized placebo-controlled trial in which 72 patients with alcohol addiction are treated with high-dose accelerated intermittent theta burst stimulation (TBS).

NCT ID: NCT05709353 Recruiting - PTSD Clinical Trials

MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder

MPATHY
Start date: September 19, 2023
Phase: Phase 2
Study type: Interventional

To explore the effectiveness of of MDMA-assisted prolonged exposure therapy in improving treatment outcomes for individuals with comorbid PTSD and alcohol use disorder in a double-blind randomised placebo-controlled trial.

NCT ID: NCT04876443 Recruiting - Alcohol Dependence Clinical Trials

Impact of COVID-19 Outbreak on the Alcohol Consumption in Patients With Alcohol-related Liver Disease (ICoLD)

Start date: October 8, 2020
Phase:
Study type: Observational

The lockdown consequent to Coronavirus outbreak has had a differential impact on the drinking behaviour on the general population. The impact is unknown on the people with underlying chronic liver disease related to alcohol as some of them may have complex psychosocial background. The alcohol consumption in people with Alcohol-related Liver Disease (ArLD) is either due to alcohol dependence or related to their lifestyle. Alcohol dependence is a chronic relapsing remitting condition and this is associated with 60% mortality at 5 years in people who continue drinking. Recovery from alcohol-use disorder (AUD) has been made more difficult during lock-down because peer support meetings such as Alcoholics Anonymous (AA) have no longer been taking place; a majority of the residential rehabilitation centres have closed or are no longer accepting admissions (PHE, 2020) and the single detoxification unit in London has been requisitioned as a COVID-19 step-down facility. The aim of the study is to understand the influence of lockdown on the craving of alcohol and severity of alcohol dependence in patients with ArLD. The results from the study will enable us to identify the factors influencing the drinking behaviour during lockdown and a subsequent impact on episodes of decompensation and mortality.

NCT ID: NCT04743024 Recruiting - Clinical trials for Alcohol Use Disorder

TREAT Child Alcohol Use Disorder (C-AUD) in Eastern Uganda

TREAT C-AUD
Start date: December 27, 2020
Phase:
Study type: Observational

The investigators will investigate the existence of alcohol drinking among children living under adult supervision and care, living within the communities. The investigators will focus on the age group 6-13 years overlapping with the recommended age for primary school attendance. The project is approaching the research topic using quantitative and qualitative methods. The TREAT C-AUD research project will therefore document to which degree alcohol drinking is a problem among children in Mbale, Eastern Uganda.

NCT ID: NCT04490330 Recruiting - Cirrhosis Clinical Trials

Screening for Alcohol-related Cognitive Impairments in Cirrhotic Patients

CirCo
Start date: August 1, 2020
Phase:
Study type: Observational

80% of patients with alcohol use disorders (AUD) present cognitive impairments, such as memory and executive functions. These disorders may have repercussions in addiction treatment by altering the patient's adherence to care. The level of impairment is dependent on the onset of addiction, and also the duration of abstinence. A complete neuropsychological evaluation is necessary to highlight cognitive impairments. In practice, the evaluation of these disorders by practitioners, is done with the help of tools of screening like the MoCa (Montreal cognitive assesment) and the BEARNI (Brief evaluation of alcohol related neuropsychological impairment). However, none of these tools have been evaluated in patients with alcoholic cirrhosis. Indeed, some studies have suggested that liver disorders including cirrhosis may be a factor aggravating cognitive disorders. The purpose of this study is to evaluate the ability of the BEARNI tool to detect alcohol-related cognitive problems in patients with alcohol-related cirrhosis.